Novartis Eye Drug Doesn't Infringe Rival's IP, UK Court Says
An appeals court in the U.K. said Wednesday that Novartis Pharmaceuticals U.K. Ltd.'s vision-loss drug Lucentis did not infringe technology patented by AstraZeneca PLC's MedImmune Ltd. unit, upholding a lower court...To view the full article, register now.
Already a subscriber? Click here to view full article